Article

SARS-CoV-2 variants: levels of neutralisation required for protective immunity

2021-08-13

Abstract excerpt

A number of SARS-CoV-2 variants of concern (VOC) have been identified that partially escape serum neutralisation activity elicited by current vaccines. Recent studies have also shown that vaccines demonstrate reduced protection against symptomatic infection with SARS-CoV-2 variants. Here we integrate published data on in vitro neutralisation and clinical protection to understand and predict vaccine efficacy agains...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 5ca8c243-0791-581b-af57-0f1a28dc7560
DOI: 10.1101/2021.08.11.21261876

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

SARS-CoV-2 variants: levels of neutralisation required for protective immunityDOI 10.1101/2021.08.11.21261876Read

What level of neutralising antibody protects from COVID-19?Semantic proximity Read

Neutralising antibodies predict protection from severe COVID-19Semantic proximity Read

Breadth of neutralising antibody responses to SARS-CoV-2 variants of concern is augmented by vaccination following prior infection: studies in UK healthcare workers and immunodeficient patientsSemantic proximity Read

Sub-optimal Neutralisation of Omicron (B.1.1.529) Variant by Antibodies induced by Vaccine alone or SARS-CoV-2 Infection plus Vaccine (Hybrid Immunity) post 6-monthsSemantic proximity Read

Reduced neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serumSemantic proximity Read

Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccinationSemantic proximity Read

Evaluation of the cross reactivity of neutralising antibody response in vaccinated human and convalescent hamster sera against SARS-CoV-2 variants up to and including JN.1 using an authentic virus neutralisation assaySemantic proximity Read

Optimised Non-Coding Regions of mRNA SARS-CoV-2 Vaccine CV2CoV Improves Homologous and Heterologous Neutralising Antibody ResponsesSemantic proximity Read

Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological studySemantic proximity Read

Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity.Semantic proximity Read

The Impact of SARS-CoV-2 Vaccination and Infection on Neutralising Antibodies: A Nation-Wide Cross-Sectional AnalysisSemantic proximity Read

Modeling the population effects of escape mutations in SARS-CoV-2 to guide vaccination strategies.Semantic proximity Read